AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01087632 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Armolipid Plus
Description: Armolipid Plus 1 tablet QD for 18 weeks
Study NCT01087632 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Armolipid Plus
Description: Armolipid Plus 1 tablet QD for 18 weeks
Study NCT02595268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.
Study NCT02595268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
Study NCT02856906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occlusal adjustment
Study NCT04583761 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems
Study NCT00599235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: 50mg 3 times daily for 7 days
Study NCT00599235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: 50mg 3 times daily for 7 days
Study NCT00599235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydralazine
Description: 25mg 3 times daily for 7 days
Study NCT00599235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydralazine
Description: 25mg 3 times daily for 7 days
Study NCT00599235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 3 times daily for 7 days
Study NCT00599235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 3 times daily for 7 days
Study NCT02938546 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
Study NCT02938546 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG
Description: 18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
Study NCT01153906 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
Study NCT03518632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval training
Description: Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.
Study NCT03518632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oncologic care
Description: Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.
Study NCT01360853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
Study NCT01360853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
Study NCT01360853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
Study NCT02077946 — intervention group
Intervention type: DRUG
Intervention: liraglutide
Description: No treatment given.
Study NCT02077946 — intervention group
Intervention type: DRUG
Intervention: sitagliptin
Description: No treatment given.
Study NCT02024841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal docetaxel
Description: Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
Study NCT01858896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-Like Peptide- 1 (GLP-1) infusion
Description: GLP-1 infusion during experimental period
Study NCT01858896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Saline Infusion
Description: Saline infusion (placebo) during experimental period
Study NCT00781872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of autologous bone marrow derived mesenchymal stem cells
Description: 60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously
Study NCT02549248 — intervention group
Intervention type: OTHER
Intervention: BAL
Description: Patients with idiopathic and non idiopathic interstitial lung diseases
Study NCT02549248 — intervention group
Intervention type: OTHER
Intervention: BW
Description: Patients with idiopathic and non idiopathic interstitial lung diseases
Study NCT02549248 — intervention group
Intervention type: OTHER
Intervention: EAC
Description: Patients with idiopathic and non idiopathic interstitial lung diseases
Study NCT02549248 — intervention group
Intervention type: OTHER
Intervention: blood specimen
Description: Patients with idiopathic and non idiopathic interstitial lung diseases
Study NCT02549248 — intervention group
Intervention type: OTHER
Intervention: Urine specimen
Description: Patients with idiopathic and non idiopathic interstitial lung diseases
Study NCT04636320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced CMR
Description: Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.
Study NCT04636320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CMR
Description: Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.
Study NCT04636320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Exercise test ECG
Description: A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
Study NCT04636320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise test ECG
Description: A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
Study NCT04636320 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers.
Study NCT04636320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers.
Study NCT04636320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Resting 12 lead ECG
Description: A resting 12 lead ECG will be performed at Day 0 visit.
Study NCT04636320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Resting 12 lead ECG
Description: A resting 12 lead ECG will be performed at Day 0 visit.
Study NCT04636320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 24 hour Holter ECG
Description: A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
Study NCT04636320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24 hour Holter ECG
Description: A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
Study NCT03459404 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Sufentanil NanoTab PCA System
Description: 15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
Study NCT03056729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB076
Description: Administered as single intravenous (IV) infusion
Study NCT03056729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as single IV infusion
Study NCT02260895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almond pre-test snack
Description: unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
Study NCT02836132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers Online
Study NCT02836132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers Online
Study NCT02836132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experience Success Virtual Reality Platform
Study NCT00654212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endo-laparoscopic approach
Description: endoluminal stenting followed by laparoscopic resection
Study NCT00654212 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: open approach
Description: emergency open surgery
Study NCT04205695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEMP (closed-ended multiport catheter) group
Description: The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
Study NCT04205695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OESP (open-ended single port catheter) group
Description: The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. hhe Non-Stimulating Needle and the Non-Stimulating open-ended catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
Study NCT04205695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia
Description: A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
Study NCT00975026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massages ± Stretches
Description: Chair Massage
Study NCT00612989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar and O6-Benzylguanine
Description: O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose.
Study NCT02284230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Study NCT02284230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03063853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Removal of surgical clips at day 4 post operative vs day 8 post operative
Description: Removal of surgical clips at day 4 post operative vs day 8 post operative
Study NCT01952769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDV9300
Description: The study will be done in the following manner:~1. Evaluation of MDV9300 and radiation-~   1. Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.~  2. Cohort B -3 patiens: if no toxicity >grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given~2. Evaluation of MDV9300 and cyclophosphamide~After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:~Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2
Study NCT03742050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
Study NCT03063853 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Elective cesarean delivery
Description: non emergent elective cesarean delivery
Study NCT01287598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
Study NCT03742050 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
Study NCT04098302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride Capsules
Description: 1 mg/day oral dutasteride (2 x 0.5 mg capsules)
Study NCT04098302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo capsules with matching appearance as Dutasteride Capsules
Study NCT01672879 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
Study NCT01672879 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SIM
Description: Intravenous infusion over 30 minutes every 2 weeks
Study NCT01672879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIM
Description: Intravenous infusion over 30 minutes every 2 weeks
Study NCT03019575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
Study NCT01489800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clear liquid diet
Description: clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
Study NCT04029831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and Ketamine Mixture (Ketofol)
Description: Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1
Study NCT02577978 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK posterior stabilized prosthesis
Study NCT02577978 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK Sphere prosthesis
Study NCT04663594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WofB
Description: Online experience designed to reduce anxiety and depression and support mental health and wellbeing
Study NCT04663594 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ashmolean Website
Description: A generic museum website owned by the Ashmolean Museum of Art and Archaeology at the University of Oxford.
Study NCT00938613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: nasal spray, one spray per nostril at time 0
Study NCT00938613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nasal spray, one spray per nostril at time 0
Study NCT00938613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: nasal spray, one spray per nostril at time 0
Study NCT01184976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3400
Description: Plasmid DNA delivered via IM injection with electroporation
Study NCT01582165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg once daily vs placebo for 6 months
Study NCT01582165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Placebo once daily vs rosuvastatin for 6 months
Study NCT03311633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous pinning time
Description: Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
Study NCT03311633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous pinning time
Description: Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
Study NCT01758432 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Apixaban
Study NCT01287598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: CYP 2C9 (warfarin) at Cycle 1
Study NCT01287598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: CYP 2C19 (omeprazole) at Cycle 1
Study NCT02011386 — intervention group
Intervention type: DRUG
Intervention: Treatment
Study NCT04819399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: Procedure: 6 weekly intravesical administration at each dose level; 3 sequential cohorts consisting of 3 patients (part I)~1. cohort 50 µg~2. cohort 70 µg~3. cohort 100 µg~Part II will be treated at recommended dose
Study NCT04209374 — intervention group
Intervention type: DEVICE
Intervention: THA with SYMBOL CUP DM HA
Study NCT02603276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols
Description: Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
Study NCT02603276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterols
Description: Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
Study NCT02603276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red Yeast Rice
Description: Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
Study NCT02603276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Yeast Rice plus Plant sterols
Description: Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
Study NCT04749147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black and White Printed Survey
Description: This survey will feature black and white text and graphics.